Motus GI Holdings, Inc. (NASDAQ: MOTS) (“Motus GI” or the “Company”) announced today that full clinical results from the Company’s REDUCE Study (“Reliable Endoscopic Diagnosis Utilizing Cleansing Enhancement”) evaluating the Pure-Vu System will be presented at Digestive Disease Week® 2019 (“DDW”), being held May 18 – 21, 2019 in San Diego, CA.
The Reduce Study data being presented at DDW is embargoed until the time of presentation. GI is a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy.
The Pure-Vu® System is a U.S. Food and Drug Administration (“FDA”) cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The device integrates with standard and slim colonoscopes to enable safe and rapid cleansing during the procedure while preserving established procedural workflow and techniques.
Details of the poster presentation are as follows:
Title: Evaluation of Bowel Cleansing Efficacy in Hospitalized Patient Population Using the Pure-Vu® System
Presenting Author: Vladimir Kushnir, M.D.
Abstract #: MO1658
Date and Time: May 20, 2019 at 12:00 p.m. PDT
Session Title: Lower GI 2
Motus GI will also have a booth at DDW located in the Exhibit Hall at Booth #4315.